NEW YORK – Medicare Administrative Contractor Palmetto GBA released a final local coverage determination for ctDNA tests detecting minimal residual disease in patients with Stage II to Stage III colon cancer, focusing specifically on Natera's Signatera test.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.